The Hemophilia Foundation of Michigan (HFM) is the recipient of a grant from Baxter Healthcare Corporation to provide national distribution of AdvoyMobile hand-held computer devices to improve access to the AdvoyCare electronic bleeding and infusion data system.
AdvoyCare, developed by Baxter Healthcare Corporation, is an easy-to-use electronic therapy and data management tool that allows patients to record bleed and infusion details. It eliminates the need for paper records and offers convenient communication and data access and storage for patients and healthcare providers.
AdvoyMobile provides access and logging capability for patients with or without Internet access using hand-held devices that can be synchronized via a personal computer or telephone line with the same secure database used by Advoy Care.
AdvoyMobile devices can be obtained free of charge by all patients nationwide, regardless of what
product is used, as long as care for their bleeding disorder is provided at a treatment center that has
registered and been trained on the use of Advoy. Order forms are available on the HFM website at www.hfmich.org and can also be obtained from treatment center providers. return to top
Following is a brief summary of an article appearing in “Molecular Therapy” March 2006 issue
University of Florida scientists say an ancient form of DNA found in fish might be useful in fighting hemophilia. The researchers say the discovery brings them closer to finding a safe way to spur production of a missing protein in patients with the most common form of the hereditary bleeding disorder.
Using a dormant strand of DNA that’s existed in fish for millions of years, the researchers successfully replaced the faulty gene responsible for the disease in neonatal mice.
“The degree to which these patients have problems from hemophilia stems from how much of this protein,
factor VIII, is missing,” said Dr. Bradley Fletcher, an assistant professor of pharmacology and one of the lead authors of the study. “If they have very low levels of it, they have lifelong problems of bleeding…”
return to top
Baxter recently announced two research collaborations with Nektar Therapeutics and Lipoxen Technologies to pursue the development of longer-acting therapeutic forms of blood clotting proteins. These agreements focus on further advancing FVIII therapy, with the objective of decreasing the frequency of infusions and improving the lives of people with hemophilia A.
Throughout the year, the Delaware Valley Chapter provides college
scholarships to young men and women affected by bleeding disorders. As a
Chapter of the National Hemophilia Foundation, we have provided more
scholarships than any other Chapter in the United States. To qualify for
financial help from the DVC, you must be a local patient treated at a local
hemophilia program in the Chapter area. You must be currently enrolled in a
college, university or post high school training program. Call the Chapter
office to find out how to apply! We are here to help you! |
